CN104937103A - ω-3五烯酸组合物及使用方法 - Google Patents

ω-3五烯酸组合物及使用方法 Download PDF

Info

Publication number
CN104937103A
CN104937103A CN201380063980.3A CN201380063980A CN104937103A CN 104937103 A CN104937103 A CN 104937103A CN 201380063980 A CN201380063980 A CN 201380063980A CN 104937103 A CN104937103 A CN 104937103A
Authority
CN
China
Prior art keywords
dha
dpa
epa
omega
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380063980.3A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·博博泰斯
阿卜杜勒·阿齐兹·法齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to CN202110585483.6A priority Critical patent/CN113274378A/zh
Publication of CN104937103A publication Critical patent/CN104937103A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
CN201380063980.3A 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法 Pending CN104937103A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110585483.6A CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US61/734,331 2012-12-06
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13
PCT/US2013/073701 WO2014089501A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110585483.6A Division CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法

Publications (1)

Publication Number Publication Date
CN104937103A true CN104937103A (zh) 2015-09-23

Family

ID=50884050

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201380063980.3A Pending CN104937103A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法
CN201380064003.5A Pending CN104902888A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法
CN202110585483.6A Pending CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法
CN202010984870.2A Pending CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201380064003.5A Pending CN104902888A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法
CN202110585483.6A Pending CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法
CN202010984870.2A Pending CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法

Country Status (9)

Country Link
EP (3) EP2929041A4 (2)
JP (4) JP6881893B2 (2)
KR (3) KR20210059779A (2)
CN (4) CN104937103A (2)
AU (7) AU2013354979A1 (2)
CA (2) CA2894183A1 (2)
IN (2) IN2015DE05009A (2)
MX (2) MX2015007082A (2)
WO (2) WO2014089511A2 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
CN109313202A (zh) * 2016-06-28 2019-02-05 雀巢产品技术援助有限公司 血脑屏障功能障碍的生物标志物
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586641A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586643A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160065A (zh) * 2005-04-21 2008-04-09 努特里希亚公司 呼吸功能不全的治疗和预防方法
CN101516202A (zh) * 2006-09-14 2009-08-26 日新Wells株式会社 一种源自鱼油的甘油酯油组合物及其制备方法
US20100069492A1 (en) * 2006-07-05 2010-03-18 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN102625847A (zh) * 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
JP2014505729A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
EP2861227A4 (en) * 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160065A (zh) * 2005-04-21 2008-04-09 努特里希亚公司 呼吸功能不全的治疗和预防方法
US20100069492A1 (en) * 2006-07-05 2010-03-18 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture
CN101516202A (zh) * 2006-09-14 2009-08-26 日新Wells株式会社 一种源自鱼油的甘油酯油组合物及其制备方法
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
CN102625847A (zh) * 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肖玫等: "深海鱼油中两种脂肪酸(E P A 和D H A)的生理功效及机理的研究进展", 《食品科学》 *

Also Published As

Publication number Publication date
CN112107570A (zh) 2020-12-22
AU2019216634A1 (en) 2019-09-05
WO2014089501A1 (en) 2014-06-12
CA2894183A1 (en) 2014-06-12
MX2015007085A (es) 2016-01-12
KR20210059779A (ko) 2021-05-25
EP2929041A1 (en) 2015-10-14
IN2015MU01505A (2) 2016-05-27
JP2021120407A (ja) 2021-08-19
KR20150103009A (ko) 2015-09-09
AU2020203658A1 (en) 2020-06-25
AU2017232203A1 (en) 2017-10-12
WO2014089511A3 (en) 2014-07-31
AU2013354969A1 (en) 2015-06-11
KR20150103671A (ko) 2015-09-11
JP2016501248A (ja) 2016-01-18
JP2016501249A (ja) 2016-01-18
CN113274378A (zh) 2021-08-20
AU2021201865A1 (en) 2021-04-22
CN104902888A (zh) 2015-09-09
IN2015DE05009A (2) 2015-12-18
JP2019172697A (ja) 2019-10-10
AU2013354979A1 (en) 2015-06-11
WO2014089511A2 (en) 2014-06-12
EP2928462A2 (en) 2015-10-14
JP6881893B2 (ja) 2021-06-02
MX2015007082A (es) 2016-01-12
EP2928462A4 (en) 2016-06-01
EP3888646A1 (en) 2021-10-06
CA2894366A1 (en) 2014-06-12
EP2929041A4 (en) 2016-06-08
AU2018229440A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
US20210205254A1 (en) Omega-3 pentaenoic acid compositions and methods of use
JP6881893B2 (ja) ω３ペンタエン酸組成物および使用方法
WO2014179325A1 (en) Omega-3 fatty acid formulations for use as pharmaceutical treatment
WO2014179341A1 (en) Treatment with omega-3 fatty acid compositions
EP2968246A1 (en) Omega-3 pentaenoic acid compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150923

RJ01 Rejection of invention patent application after publication